242 filings
Page 6 of 13
8-K
kocp6bk2p
19 Jun 20
Departure of Directors or Certain Officers
5:01pm
8-K
dm651ztr0krektqfx1
28 May 20
Other Events
4:30pm
8-K
xxgv0cvo0padjtdtpa0
22 May 20
Entry into a Material Definitive Agreement
5:25pm
8-K
jd77bup32tm3atma6zrs
21 May 20
April 2020 sales of Mytesi® generate gross accounts receivable of $2,753,639
12:00am
8-K
k67bx84 moeaeg3in
18 May 20
Jaguar Health, Inc. Reports 2020 First Quarter Financial Results
9:29am
8-K
mquvzc4 m4vr
12 May 20
Regulation FD Disclosure
1:42pm
8-K
g9w7pim9nl0gh41wo
8 May 20
Regulation FD Disclosure
5:07pm
8-K
pnqq9c
16 Apr 20
Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug Candidate
8:31am
8-K
ptr58j x1nkdma2a
10 Apr 20
Other Events
5:00pm
8-K
5p56txzrgqo4dbh
6 Apr 20
Jaguar Health Reports 2019 Financial Results and Business Updates
8:12am
8-K
hme9 8p1nwq
3 Apr 20
Regulation FD Disclosure
8:30am
8-K
6f7j2xpj1 051
26 Mar 20
Entry into a Material Definitive Agreement
5:00pm
8-K
vi4y9p01zf9 wy
23 Mar 20
Other Events
8:00am
8-K
z5kbq5kv0r jtr46b
6 Mar 20
Jaguar Health Secures Non-dilutive Capital Through Sale of Royalty Rights Related to Future Mytesi Revenue Stream
5:06pm
8-K
5ca81
28 Feb 20
Entry into a Material Definitive Agreement
4:00pm
8-K
js2msbpdsd6
27 Feb 20
Departure of Directors or Certain Officers
12:00am
8-K
c72zw1nx ys2
31 Dec 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:06pm
8-K
yjun8vam8avcxcm1ey9s
26 Dec 19
Entry into a Material Definitive Agreement
4:30pm
8-K
cf8b530
15 Nov 19
Jaguar Health, Inc. Reports 2019 Third Quarter Financial Results
4:00pm
8-K
0yu53kc
14 Nov 19
Regulation FD Disclosure
4:47pm